Emerging research suggest Retatru tide , a dual agonist targeting both GLP-1 and GIP , could offer a significant step forward for body treatment. Preliminary patient investigations have demonstrated substantial losses in visceral mass , potentially surpassing other weight-loss therapies . However , more evaluation is required to fully understand it